Tirzepatide is a dual GIP and GLP-1 receptor agonist that enhances insulin secretion, reduces appetite and promotes weight loss.
Recommended for:
Studies:
According to SURPASS and SURMOUNT trials, Tirzepatide demonstrated significant HbA1c reduction and weight loss compared to other GLP-1 receptor agonists.
The drug is administered subcutaneously once weekly. Dosage should be individually selected by a physician, starting from the lowest dose and gradually increasing.
Contraindications:
Side effects:









